CVKD
Cadrenal Therapeutics, Inc.
$4.21
-5.18%
$12.2M
No data for this timeframe.
Vol
Market Cap$12.2M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders4 funds
Inst. Value$373.5K
Inst. Activity1 buys / 2 sells
Insider Activity0B / 9S
Insider Net $-$115.4K
SEC Reports5
Press Releases2
Recent Activity
Jun 5, 2026
Insider
Pham Quang X sold 2,064 shares
CEO and Chairman @ $4.42 ($9.1K)
Jun 4, 2026
Insider
Pham Quang X sold 3,898 shares
CEO and Chairman @ $4.41 ($17.2K)
Jun 3, 2026
Insider
Pham Quang X sold 2,323 shares
CEO and Chairman @ $4.26 ($9.9K)
May 19, 2026
routine
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
<p>PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD),
May 7, 2026
SEC
Cadrenal Therapeutics reported Q1 2026 EPS of -$1.04, beating the -$1.57 consensus by 33.8%. The company also announced
PRESS-RELEASE — Impact 6/10
Apr 30, 2026
SEC
Cadrenal Therapeutics announced successful completion of its End-of-Phase 2 meeting with the FDA, receiving guidance to
8-K — Impact 7/10
Apr 21, 2026
SEC
Cadrenal Therapeutics reported a net loss of $3.0 million for Q4 2025, an improvement from $4.2 million in the prior yea
8-K — Impact 6/10
Inst.
MORGAN STANLEY — DOUBLED
880 shares ($12.2K)
Price Targets
$27.67
+600.4% upside
Strong Buy
Current $3.95
Low $13.00
Median $25.00
High $45.00
3 analysts
$13.00
$45.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.64 ▼ -18.0% | $-1.95 — $-1.33 | 12% YoY | 2 |
| Next Q | $-1.45 ▲ +4.3% | $-2.10 — $-0.79 | -10% YoY | 2 |
| Current FY | $-5.88 ▼ -8.4% | $-7.74 — $-4.01 | 12% YoY | 2 |
| Next FY | $-3.91 | $-3.91 — $-3.91 | 33% YoY | 1 |
Latest Reports
BULLISH
PRESS-RELEASE
6/10
Cadrenal Therapeutics reported Q1 2026 EPS of -$1.04, beating the -$1.57 consensus by 33.8%. The company also announced
May 7, 2026
BULLISH
8-K
7/10
Cadrenal Therapeutics announced successful completion of its End-of-Phase 2 meeting with the FDA, receiving guidance to
Apr 30, 2026
MIXED
Press
6/10
Cadrenal Therapeutics reported financial results for Q4 and full year 2025, highlighting a $3.0M net loss for the quarte
Mar 31, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $365.5K | NEW |
| MORGAN STANLEY | $7.3K | DOUBLED |
| WELLS FARGO & COMPANY/MN | $671.00 | — |
| BANK OF AMERICA CORP | $7.00 | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 5, 2026 | Pham Quang | SELL | $9.1K |
| Jun 4, 2026 | Pham Quang | SELL | $17.2K |
| Jun 3, 2026 | Pham Quang | SELL | $9.9K |
| Jun 2, 2026 | Pham Quang | SELL | $1.6K |
| May 29, 2026 | Pham Quang | SELL | $1.5K |
4 institutional holders with $373.5K total value (55,092 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, WELLS.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 53,912 | $365.5K | 97.9% | NEW |
| 2 | MORGAN STANLEY | 1,080 | $7.3K | 2.0% | DOUBLED +104.7% |
| 3 | WELLS FARGO & COMPANY/MN | 99 | $671.00 | 0.2% | — |
| 4 | BANK OF AMERICA CORP /DE/ | 1 | $7.00 | 0.0% | NEAR_EXIT -92.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 430 | 880 | +104.7% | $12.2K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 326 | 35 | -89.3% | $484.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 14 | 1 | -92.9% | $14.00 | 2025-Q3 |
| MORGAN STANLEY | TRIM | 1,130 | 430 | -61.9% | $5.2K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 8,445 | 326 | -96.1% | $3.9K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 11 | 14 | +27.3% | $169.00 | 2025-Q2 |
| VANGUARD GROUP INC | NEW | — | 45,633 | — | $804.5K | 2025-Q1 |
| UBS Group AG | DOUBLED | 2,172 | 8,445 | +288.8% | $148.9K | 2025-Q1 |
| UBS Group AG | NEW | — | 2,172 | — | $31.5K | 2024-Q4 |
| MORGAN STANLEY | NEW | — | 1,146 | — | $16.6K | 2024-Q4 |
1 unique insiders with 9 transactions. Net insider value: -$115.4K ($0.00 bought, $115.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Pham Quang X | CEO and Chairman | SELL | 2,064 | $4.42 | $9.1K |
| Jun 4, 2026 | Pham Quang X | CEO and Chairman | SELL | 3,898 | $4.41 | $17.2K |
| Jun 3, 2026 | Pham Quang X | CEO and Chairman | SELL | 2,323 | $4.26 | $9.9K |
| Jun 2, 2026 | Pham Quang X | CEO and Chairman | SELL | 349 | $4.46 | $1.6K |
| May 29, 2026 | Pham Quang X | CEO and Chairman | SELL | 303 | $5.01 | $1.5K |
| May 28, 2026 | Pham Quang X | CEO and Chairman | SELL | 2,989 | $4.93 | $14.7K |
| May 22, 2026 | Pham Quang X | CEO and Chairman | SELL | 1,165 | $5.69 | $6.6K |
| May 12, 2026 | Pham Quang X | CEO and Chairman | SELL | 3,298 | $5.28 | $17.4K |
| May 11, 2026 | Pham Quang X | CEO and Chairman | SELL | 6,476 | $5.76 | $37.3K |
5 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 1 mixed, 1 neutral. Avg impact: 5.6/10.
BULLISH
PRESS-RELEASE
6/10
Cadrenal Therapeutics reported Q1 2026 EPS of -$1.04, beating the -$1.57 consensus by 33.8%. The com
May 7, 2026
BULLISH
8-K
7/10
Cadrenal Therapeutics announced successful completion of its End-of-Phase 2 meeting with the FDA, re
Apr 30, 2026
MIXED
8-K
6/10
Cadrenal Therapeutics reported a net loss of $3.0 million for Q4 2025, an improvement from $4.2 mill
Apr 21, 2026
BEARISH
424B5
6/10
Cadrenal Therapeutics amended the exercise price of existing warrants to purchase 571,430 shares fro
Apr 1, 2026
NEUTRAL
8-K
3/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing includes I
Mar 12, 2026
Current analyst consensus: Strong Buy (88% buy). Based on 8 analysts: 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$27.67 mean target
+600.4% upside
Strong Buy (3.00)
$13.00 Low
$45.00 High
| Metric | Value |
|---|---|
| Current Price | $3.95 |
| Target Low | $13.00 |
| Target Mean | $27.67 |
| Target Median | $25.00 |
| Target High | $45.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.64 | $-1.95 | $-1.33 | 12.3% | -18.0% | — | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-1.45 | $-2.10 | $-0.79 | -10.3% | +4.3% | — | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-5.88 | $-7.74 | $-4.01 | 11.5% | -8.4% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-3.91 | $-3.91 | $-3.91 | 33.5% | — | 1↑ 0↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.640 | |
| 7d ago | $-1.640 | |
| 30d ago | $-1.390 | -0.250 |
| 60d ago | $-1.390 | -0.250 |
| 90d ago | $-1.390 | -0.250 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 19, 2026
routine
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
<p>PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing
May 7, 2026
earnings
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
Official FDA meeting minutes and Phase 2 data provide guidance on the pivotal Phase 3 registration path for CAD-1005 in heparin-induced thrombocytopen
May 6, 2026
earnings_calendar
CVKD Q1 2026 Earnings Scheduled — 2026-05-06
Mar 31, 2026
earnings
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal’s near-term development priority; broader 1
Mar 12, 2026
fda
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
<p>PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovati
Mar 11, 2026
earnings_calendar
CVKD Q4 2025 Earnings Before Market Open — 2026-03-11